UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid‐based therapies to improve on the poor current therapeutic outcomes

British journal of pharmacology, 2019-05, Vol.176 (10), p.1370-1383

Fernández‐Ruiz, Javier

2019

Volltextzugriff (PDF)

The endocannabinoid system as a target for the treatment of motor dysfunction

British journal of pharmacology, 2009-04, Vol.156 (7), p.1029-1040

Fernández‐Ruiz, Javier

2009

Volltextzugriff (PDF)

From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline

British journal of pharmacology, 2024-03, Vol.181 (6), p.755-759

2024

Volltextzugriff (PDF)

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.323-333

2013

Volltextzugriff (PDF)

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Biochemical pharmacology, 2018-11, Vol.157, p.67-84

2018

Volltextzugriff (PDF)

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor

Chemistry : a European journal, 2020-12, Vol.26 (68), p.15839-15842

2020

Volltextzugriff (PDF)

A Systematic Review of Peer Assessment Design Elements

Educational psychology review, 2023-03, Vol.35 (1), p.18, Article 18

2023

Volltextzugriff (PDF)

Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

British journal of pharmacology, 2021-03, Vol.178 (6), p.1253-1256

2021

Volltextzugriff (PDF)

Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

Brain pathology (Zurich, Switzerland), 2021-11, Vol.31 (6), p.n/a

2021

Volltextzugriff (PDF)

Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia

British journal of pharmacology, 2016-07, Vol.173 (13), p.2069-2079

2016

Volltextzugriff (PDF)

Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

British journal of pharmacology, 2021-03, Vol.178 (6), p.1373-1387

2021

Volltextzugriff (PDF)

Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders

Frontiers in neuroscience, 2016-09, Vol.10, p.406-406

2016

Volltextzugriff (PDF)

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

Brain (London, England : 1878), 2009-11, Vol.132 (11), p.3152-3164

2009

Volltextzugriff (PDF)

VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB2 receptor‐dependent pathways

British journal of pharmacology, 2018-10, Vol.175 (19), p.3813-3831

2018

Volltextzugriff (PDF)

restricted population of CB₁ cannabinoid receptors with neuroprotective activity

Proceedings of the National Academy of Sciences - PNAS, 2014-06, Vol.111 (22), p.8257-8262

2014

Volltextzugriff (PDF)

Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease

Molecules (Basel, Switzerland), 2019-07, Vol.24 (15), p.2702

2019

Volltextzugriff (PDF)

Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease

Molecules (Basel, Switzerland), 2021-05, Vol.26 (11), p.3245

2021

Volltextzugriff (PDF)

Changes in CB1 and CB2 receptors in the post‐mortem cerebellum of humans affected by spinocerebellar ataxias

British journal of pharmacology, 2014-03, Vol.171 (6), p.1472-1489

2014

Volltextzugriff (PDF)

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

Journal of neuroscience research, 2011-09, Vol.89 (9), p.1509-1518

2011

Volltextzugriff (PDF)

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

Journal of neuroinflammation, 2023-05, Vol.20 (1), p.108-108, Article 108

2023

Volltextzugriff (PDF)

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Biomolecules (Basel, Switzerland), 2022-08, Vol.12 (9), p.1200

2022

Volltextzugriff (PDF)

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

Brain (London, England : 1878), 2011-01, Vol.134 (Pt 1), p.119-136

2011

Volltextzugriff (PDF)

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

Glia, 2009-08, Vol.57 (11), p.1154-1167

2009

Volltextzugriff (PDF)

Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders

CNS neuroscience & therapeutics, 2010-06, Vol.16 (3), p.e72-e91

2010

Volltextzugriff (PDF)

1 – 25 von 484

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(446)
Mit Volltextzugriff
(436)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid‐based therapies to improve on the poor current therapeutic outcomes

The endocannabinoid system as a target for the treatment of motor dysfunction

From Alzheimer's disease to vascular dementia: Different roads leading to cognitive decline

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor

A Systematic Review of Peer Assessment Design Elements

Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis

Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP‐43 transgenic mice, a model of amyotrophic lateral sclerosis

Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia

Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis

Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity

VCE‐004.3, a cannabidiol aminoquinone derivative, prevents bleomycin‐induced skin fibrosis and inflammation through PPARγ‐ and CB2 receptor‐dependent pathways

restricted population of CB₁ cannabinoid receptors with neuroprotective activity

Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease

Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell and Murine Models of Parkinson’s Disease

Changes in CB1 and CB2 receptors in the post‐mortem cerebellum of humans affected by spinocerebellar ataxias

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration

Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice

New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease

Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders

Suchergebnisse filtern